查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570848

抗生素抗药性市场：按类型、作用机制、活性频谱、药物类别、给药途径、最终用户、分销管道 - 2025-2030 年全球预测

Antibiotic Resistance Market by Type, Mechanism of Action, Spectrum of Activity, Drug Class, Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗生素抗药性市场价值为90.2亿美元，预计到2024年将达到98.7亿美元，复合年增长率为9.40%，到2030年将达到169.3亿美元。

抗生素抗药性是一个重要的公共卫生问题，是指细菌和其他微生物抵抗曾经成功治疗感染疾病的药物作用的能力。这种抗药性对全球构成重大威胁，影响人类和动物健康，对农业、医疗保健和经济稳定产生重大影响。解决抗生素抗药性问题的必要性在于，普通治疗可能会变得无效，导致病情延长和死亡率增加。它们的应用范围广泛，包括在医学领域（迫切需要新型抗生素）和在农业领域（政策变化要求负责任地使用）。主要的最终用途部门是医疗保健提供者、製药公司和监管机构。

主要市场统计
基准年[2023] 90.2亿美元
预测年份 [2024] 98.7亿美元
预测年份 [2030] 169.3亿美元
复合年增长率（%） 9.4%

市场驱动因素包括抗药性感染疾病的增加、政府谨慎使用抗生素的措施以及增加对噬菌体和胜肽等替代治疗方法研发的资金。生物技术产业的创新，特别是快速诊断工具和个人化医疗方面的创新，预示着巨大的商机。然而，挑战包括由于高成本和监管严格而导致新抗生素开发速度缓慢等限制。此外，在监管较少的市场中滥用抗生素的可能性以及全球在获得新治疗方法的差异是影响成长的其他因素。

有很多机会可以增强快速诊断技术并开发替代疗法，例如益生菌和疫苗，以最大限度地减少滥用并保持抗生素的有效性。对公司的建议包括投资于合作研究和开发以及倡导支持性政策框架以加快药物核准。创新研究领域，例如利用 CRISPR 开发标靶抗生素，前景尤其光明。市场在技术进步和监管条件的推动下高度活跃，对于那些希望在利用新的科学突破的同时缓解市场状况的相关人员来说，这是一个紧迫的机会主义领域。

市场动态：揭示快速发展的抗生素抗药性市场的关键市场洞察

供需的动态交互作用正在改变抗生素抗药性市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，以及消费行为及其对製造成本的影响，还可以更清楚地了解其对采购的影响趋势。

波特的五力：驾驭抗生素抗药性市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗生素抗药性市场的外部影响

外部宏观环境因素在塑造抗生素抗药性市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗生素抗药性市场的竞争格局

对抗生素抗药性市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗生素抗药性市场供应商的绩效评估

FPNV定位矩阵是评估抗生素抗药性市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了抗生素抗药性市场的成功之路

抗生素抗药性市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 与抗生素抗药性感染疾病相关的医疗成本上升有助于市场成长
      • 快速诊断检测的广泛采用推动了抗生素抗药性的市场需求
      • 透过加强製药公司和研究机构之间的合作解决抗生素抗药性问题
      • 新兴市场对抗生素抗药性解决方案表现出极大的兴趣和潜力
    • 抑制因素
      • 监管障碍和核准延迟阻碍了新抗生素的采用
    • 机会
      • 开发针对抗生素抗药性菌株的新型抗生素，以满足重要的医疗需求
      • 引进先进的诊断工具来早期发现和管理抗生素抗药性感染疾病
      • 透过寻找噬菌体和益生菌等替代疗法来消除抗生素抗药性
    • 任务
      • 製药公司与学术机构在抗生素研究方面缺乏合作
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章抗生素抗药性市场：依类型

  • 介绍
  • 抗菌产品
  • 抗真菌产品
  • 驱虫药
  • 抗病毒产品

第七章抗生素抗药性市场：按作用机制

  • 介绍
  • 细胞壁合成抑制剂
  • DNA旋转酶抑制剂
  • 蛋白质合成抑制剂
  • RNA聚合酵素抑制剂

第八章抗生素抗药性市场：依活动频谱

  • 介绍
  • 广效抗生素
  • 窄谱抗生素

第九章抗生素抗药性市场：依药物类别

  • 介绍
  • 头孢菌素
  • Fluoroquinolones
  • 大环内酯
  • 青霉素
  • 四环霉素

第10章抗生素抗药性市场：依给药途径

  • 介绍
  • 静脉
  • 口服

第十一章抗生素抗药性市场：依最终用户分类

  • 介绍
  • 诊所
  • 居家医疗
  • 医院

第十二章抗生素抗药性市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第十三章美洲抗生素抗药性市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太抗生素抗药性市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲抗生素抗药性市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C629188E6

The Antibiotic Resistance Market was valued at USD 9.02 billion in 2023, expected to reach USD 9.87 billion in 2024, and is projected to grow at a CAGR of 9.40%, to USD 16.93 billion by 2030.

Antibiotic resistance, a critical public health issue, refers to the ability of bacteria and other microbes to resist the effects of drugs that once successfully treated infections. This resistance poses a significant threat globally, affecting both human and animal health, with substantial implications for agriculture, healthcare, and economic stability. The necessity for addressing antibiotic resistance lies in its potential to render common treatments ineffective, leading to prolonged illnesses and increased mortality. Applications are vast, including in healthcare, where new classes of antibiotics are urgently needed, and agriculture, where responsible usage is being driven by policy changes. The end-use sectors are largely healthcare providers, pharmaceutical companies, and regulatory bodies.

KEY MARKET STATISTICS
Base Year [2023] USD 9.02 billion
Estimated Year [2024] USD 9.87 billion
Forecast Year [2030] USD 16.93 billion
CAGR (%) 9.4%

Market insights reveal key growth drivers such as the rising incidence of drug-resistant infections, governmental initiatives for prudent antibiotic use, and increased funding for R&D in alternative treatments like bacteriophages and antimicrobial peptides. The biotechnology industry's innovations, particularly in rapid diagnostic tools and personalized medicine, herald substantial opportunities. However, limitations such as the slow pace of new antibiotics development due to high costs and stringent regulations pose challenges. Additional factors affecting growth include the potential misuse of antibiotics in low-regulation markets and disparities in global access to new treatments.

Opportunities abound in enhancing rapid diagnostic technologies, which can minimize misuse and conserve antibiotic efficacy, and developing alternative therapies such as probiotics and vaccines. Recommendations for businesses include investing in collaborative R&D efforts and advocating for supportive policy frameworks to expedite drug approvals. Innovative research areas like harnessing CRISPR-based technologies for targeted antimicrobial therapies are particularly promising. The market is highly dynamic, driven by technological advancements and regulatory landscapes, presenting an urgent yet opportunistic field for stakeholders aiming to mitigate antibiotic resistance while capitalizing on emerging scientific breakthroughs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibiotic Resistance Market

The Antibiotic Resistance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High healthcare costs associated with antibiotic-resistant infections contributing to market growth
    • Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
    • Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
    • Emerging markets showing significant interest and potential in antibiotic resistance solutions
  • Market Restraints
    • Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
  • Market Opportunities
    • Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
    • Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
    • Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
  • Market Challenges
    • Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research

Porter's Five Forces: A Strategic Tool for Navigating the Antibiotic Resistance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibiotic Resistance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibiotic Resistance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibiotic Resistance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibiotic Resistance Market

A detailed market share analysis in the Antibiotic Resistance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibiotic Resistance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibiotic Resistance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibiotic Resistance Market

A strategic analysis of the Antibiotic Resistance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibiotic Resistance Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibiotic Resistance Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antibacterial Products, Antifungal Products, Antiparasitic Products, and Antiviral Products.
  • Based on Mechanism of Action, market is studied across Cell Wall Synthesis Inhibitors, DNA Gyrase Inhibitors, Protein Synthesis Inhibitors, and RNA Polymerase Inhibitors.
  • Based on Spectrum of Activity, market is studied across Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics.
  • Based on Drug Class, market is studied across Cephalosporins, Fluoroquinolones, Macrolides, Penicillins, and Tetracyclines.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High healthcare costs associated with antibiotic-resistant infections contributing to market growth
      • 5.1.1.2. Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
      • 5.1.1.3. Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
      • 5.1.1.4. Emerging markets showing significant interest and potential in antibiotic resistance solutions
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
      • 5.1.3.2. Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
      • 5.1.3.3. Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibiotic Resistance Market, by Type

  • 6.1. Introduction
  • 6.2. Antibacterial Products
  • 6.3. Antifungal Products
  • 6.4. Antiparasitic Products
  • 6.5. Antiviral Products

7. Antibiotic Resistance Market, by Mechanism of Action

  • 7.1. Introduction
  • 7.2. Cell Wall Synthesis Inhibitors
  • 7.3. DNA Gyrase Inhibitors
  • 7.4. Protein Synthesis Inhibitors
  • 7.5. RNA Polymerase Inhibitors

8. Antibiotic Resistance Market, by Spectrum of Activity

  • 8.1. Introduction
  • 8.2. Broad-Spectrum Antibiotics
  • 8.3. Narrow-Spectrum Antibiotics

9. Antibiotic Resistance Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Cephalosporins
  • 9.3. Fluoroquinolones
  • 9.4. Macrolides
  • 9.5. Penicillins
  • 9.6. Tetracyclines

10. Antibiotic Resistance Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral

11. Antibiotic Resistance Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Antibiotic Resistance Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Americas Antibiotic Resistance Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Antibiotic Resistance Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Antibiotic Resistance Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Limited
  • 6. Bayer AG
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Limited
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIBIOTIC RESISTANCE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBIOTIC RESISTANCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBIOTIC RESISTANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBIOTIC RESISTANCE MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIBACTERIAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIFUNGAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIPARASITIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIVIRAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DNA GYRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RNA POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BROAD-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY NARROW-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 328. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2023